Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879469 | 0.86 | LMNA (0.75) | LMNAGAAALOX5MAOACACNA1B | |
| SCHEMBL13879428 | 0.84 | LMNA (0.49) | LMNAMEN1KMT2AMGLLPOLB | |
| SCHEMBL13879422 | 0.81 | LMNA (0.57) | LMNAGAAMEN1KMT2ARAB9A | |
| SCHEMBL13879488 | 0.81 | MAPT (0.50) | LMNAGAAMEN1KMT2ACYP1A2 | |
| SCHEMBL11613980 | 0.81 | LMNA (0.56) | LMNAGAAALOX5MAOACACNA1B | |
| SCHEMBL14440709 | 0.76 | LMNA (0.39) | LMNACYP1A2POLB | |
| SCHEMBL13879479 | 0.73 | ALDH1A1 (0.59) | LMNAGAAMEN1KMT2ACYP1A2 | |
| SCHEMBL10575698 | 0.73 | GAA (0.50) | LMNAGAAALOX5MAOACACNA1B | |
| SCHEMBL3285739 | 0.72 | CYP1A2 (0.58) | LMNAGAAALOX5CACNA1BAPBA1 | |
| SCHEMBL14440705 | 0.71 | AR (0.47) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | LMNA 2024/4885GAA 463/4885ALOX5 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.